# US 2014/0193458 A1 · Method of vaccination comprising a histone deacetylase inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0193458 A1
- Document ID: US20140193458A1
- Status: Published application
- Kind: A1
- Application number: 14/004,546
- Filed: 2012-03-09
- Published: 2014-07-10
- Earliest claimed: 2011-03-11
- Assignees: Turnstone Limited Partnership
- Inventors: Byram Bridle; Brian Lichty; Yonghong Wan; Jean-Simon Diallo; Chantal Lemay; John Bell
- Web page: https://patentgrep.com/patent/US20140193458A1

## CPC

- A61K 39/29: Hepatitis virus
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/4406: only substituted in position 3, e.g. zimeldine (nicotinic acid A61K31/455)
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 35/766: Rhabdovirus, e.g. vesicular stomatitis virus
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 38/15: Depsipeptides; Derivatives thereof
- A61K 38/164: {from bacteria}
- A61K 39/0011: {Cancer antigens}
- A61K 39/001106: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4}
- A61K 39/001181: {Alpha-feto protein}
- A61K 39/001182: {Carcinoembryonic antigen [CEA]}
- A61K 39/001186: {MAGE}
- A61K 39/001188: {NY-ESO}
- A61K 39/001191: {Melan-A/MART}
- A61K 39/001192: {Glycoprotein 100 [Gp100]}
- A61K 39/02: Bacterial antigens
- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61K 39/12: Viral antigens
- A61K 39/165: Mumps or measles virus
- A61K 39/17: Newcastle disease virus
- A61K 39/205: Rhabdoviridae, e.g. rabies virus
- A61K 39/285: Vaccinia virus or variola virus
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2760/20232: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2760/20243: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.

## Claims

### Claim 1

A vaccination method comprising administering to a mammal a histone deacetylase inhibitor and a vaccine that delivers an antigen to which the mammal has a pre-existing immunity.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antigen is selected from the group consisting of include tumour antigens, antigens from viral pathogens and antigens from bacterial pathogens.

### Claim 3 (depends on 2)

The method of claim 2, wherein the tumour antigen is selected from the group consisting of alphafetoprotein (AFP), carcinoembryonic antigen (CEA), CA 125, Her2, dopachrome tautomerase (DCT), GP100, MART1, MAGE protein, NY-ESO1, HPV E6 and HPV E7.

### Claim 4 (depends on 1)

The method of claim 1, wherein the antigen is from a pathogenic organism selected from the group consisting of HIV, HepC, Fly, LCMV, Ebola virus and mycobacterium tuberculosis.

### Claim 5 (depends on 1)

The method of claim 1, wherein the histone deacetylase inhibitor is selected from the group consisting of hydroxamic, benzamides, cyclic tetrapeptides, depsipeptides, electrophilic ketones, and aliphatic acid compounds.

### Claim 6 (depends on 5)

The method of claim 5, wherein the hydroxamic acids are selected from vorinostat (SAHA), belinostat (PXD101), LAQ824, trichostatin A and panobinostat (LBH589); the benzamides are selected from entinostat (MS-275), CI994 and mocetinostat (MGCD0103); the cyclic tetrapeptide is trapoxin B); and the aliphatic acid compounds may be phenylbutyrate or valproic acid.

### Claim 7 (depends on 1)

The method of claim 1, wherein the vaccine is a viral vaccine that expresses the antigen.

### Claim 8 (depends on 1)

The method of claim 1, wherein the viral vaccine is an oncolytic virus.

### Claim 9 (depends on 8)

The method of claim 8, wherein the oncolytic virus is selected from the group consisting of rhabdoviruses, measles, vaccinia, herpes, myxoma, parvoviral, Newcastle disease, adenovirus and semliki forest virus.

### Claim 10 (depends on 8)

The method of claim 8, wherein the oncolytic virus is a vesiculovirus selected from the group consisting of vesicular stomatitis virus (VSV), Maraba virus, Ephemerovirus, Cytorhabdovirus, Nucleorhabdovirus and Lyssavirus virus.

### Claim 11 (depends on 1)

The method of claim 1, wherein the vaccine induces expression of type I interferon.

### Claim 12 (depends on 1)

The method of claim 1, wherein the vaccine is an antigen-presenting B-cell.

### Claim 13 (depends on 1)

The method of claim 1, wherein the vaccine is administered in combination with an agent that induces expression of type I interferon.

### Claim 14

A composition comprising a vaccine and a histone deacetylase inhibitor.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the vaccine is a viral vaccine.

### Claim 16 (depends on 14)

The composition of claim 14, wherein the vaccine induces type I interferon.

### Claim 17 (depends on 14)

The composition of claim 14, wherein the histone deacetylase inhibitor is selected from the group consisting of hydroxamic, benzamides, cyclic tetrapeptides, depsipeptides, electrophilic ketones, and aliphatic acid compounds.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the hydroxamic acids are selected from vorinostat (SAHA), belinostat (PXD101), LAQ824, trichostatin A and panobinostat (LBH589); the benzamides are selected from entinostat (MS-275), CI994 and mocetinostat (MGCD0103); the cyclic tetrapeptide is trapoxin B); and the aliphatic acid compounds may be phenylbutyrate or valproic acid.

### Claim 19 (depends on 14)

The composition of claim 14, additionally comprising an agent that induces expression of type I interferon.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the agent is selected from the group consisting of a toll-like receptor ligand, imiquimod, polyinosine-polycytidylic acid (polyI:C), CpG ODN, imidazoquinoline, monophosphoryl lipid A, flagellin, FimH and N-glycolyted muramyldipeptide